321 related articles for article (PubMed ID: 33114390)
1. DMARDs-Gut Microbiota Feedback: Implications in the Response to Therapy.
Zaragoza-García O; Castro-Alarcón N; Pérez-Rubio G; Guzmán-Guzmán IP
Biomolecules; 2020 Oct; 10(11):. PubMed ID: 33114390
[TBL] [Abstract][Full Text] [Related]
2. Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
Fan J; Jiang T; He D
Front Immunol; 2023; 14():1189036. PubMed ID: 37841256
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Gut Microbiota in Rheumatoid Arthritis Patients: Disease-Related Dysbiosis and Modifications Induced by Etanercept.
Picchianti-Diamanti A; Panebianco C; Salemi S; Sorgi ML; Di Rosa R; Tropea A; Sgrulletti M; Salerno G; Terracciano F; D'Amelio R; Laganà B; Pazienza V
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261687
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with the composition of the gut microbiome in patients with established rheumatoid arthritis and its value for predicting treatment responses.
Koh JH; Lee EH; Cha KH; Pan CH; Kim D; Kim WU
Arthritis Res Ther; 2023 Mar; 25(1):32. PubMed ID: 36864473
[TBL] [Abstract][Full Text] [Related]
5. The role of microbiome in rheumatoid arthritis treatment.
Bodkhe R; Balakrishnan B; Taneja V
Ther Adv Musculoskelet Dis; 2019; 11():1759720X19844632. PubMed ID: 31431810
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics in rheumatoid arthritis.
Sen D; Paul JR; Ranganathan P
Methods Mol Biol; 2014; 1175():625-60. PubMed ID: 25150878
[TBL] [Abstract][Full Text] [Related]
7. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
[TBL] [Abstract][Full Text] [Related]
9. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
10. Triggers and regulation: the gut microbiome in rheumatoid arthritis.
Mahroum N; Seida R; Shoenfeld Y
Expert Rev Clin Immunol; 2023; 19(12):1449-1456. PubMed ID: 37712213
[TBL] [Abstract][Full Text] [Related]
11. [DMARDs (disease-modifying antirheumatic drugs)].
Tanaka E; Yamanaka H
Nihon Rinsho; 2013 Jul; 71(7):1199-206. PubMed ID: 23961667
[TBL] [Abstract][Full Text] [Related]
12. Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis.
Williams HJ
Br J Rheumatol; 1995 Nov; 34 Suppl 2():96-9. PubMed ID: 8535657
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota and rheumatoid arthritis: From pathogenesis to novel therapeutic opportunities.
Zhao T; Wei Y; Zhu Y; Xie Z; Hai Q; Li Z; Qin D
Front Immunol; 2022; 13():1007165. PubMed ID: 36159786
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics in rheumatoid arthritis.
Ranganathan P
Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
16. [ Bone and cartilage destruction in RA and its intervention. Disease-modifying antirheumatic drugs].
Ichikawa N; Yamanaka H
Clin Calcium; 2012 Feb; 22(2):215-21. PubMed ID: 22298075
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid arthritis and the intestinal microbiome: probiotics as a potential therapy.
Yang Y; Hong Q; Zhang X; Liu Z
Front Immunol; 2024; 15():1331486. PubMed ID: 38510244
[TBL] [Abstract][Full Text] [Related]
18. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
Feely MG; O'Dell JR
Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
[TBL] [Abstract][Full Text] [Related]
19. Serum Levels of IFABP2 and Differences in
Zaragoza-García O; Castro-Alarcón N; Pérez-Rubio G; Falfán-Valencia R; Briceño O; Navarro-Zarza JE; Parra-Rojas I; Tello M; Guzmán-Guzmán IP
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768285
[TBL] [Abstract][Full Text] [Related]
20. Troublesome friends within us: the role of gut microbiota on rheumatoid arthritis etiopathogenesis and its clinical and therapeutic relevance.
Reyes-Castillo Z; Valdés-Miramontes E; Llamas-Covarrubias M; Muñoz-Valle JF
Clin Exp Med; 2021 Feb; 21(1):1-13. PubMed ID: 32712721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
